Next-Generation Therapies for Type 1 Diabetes: From Stem Cells to Immune-Adaptive Treatments
Featuring: Jeffrey R. Millman, PhD
Panel: Nathaniel Hogrebe, PhD, Stephen Stone, MD, and Xiaoxiao (Xiao) Wan, MD, PhD
Type 1 diabetes (T1D) results from the immune system destroying insulin-producing pancreatic beta cells, requiring lifelong insulin therapy and careful glucose monitoring. However, rapid advances in regenerative medicine, bioengineering, and immunotherapy are opening realistic paths toward transformative treatments and potentially functional cures.
This panel brings together leading researchers working at the forefront of these innovations. Topics will include stem cell-derived islet replacement therapies designed to restore natural insulin production, strategies to protect transplanted cells from immune attack, and emerging approaches to modulate or retrain the immune system itself. Speakers will also discuss advances in cell manufacturing, tissue engineering, and translational pathways that are accelerating movement from laboratory discovery to clinical application.
Together, these perspectives highlight how interdisciplinary science is reshaping the therapeutic landscape for T1D. Attendees will gain insight into where the field stands today, what breakthroughs are on the horizon, and the challenges that must still be overcome to deliver durable, widely accessible treatments for people living with T1D.
